olamlo hct 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack
accord healthcare pty ltd - amlodipine besilate, quantity: 6.95 mg; hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; silicified microcrystalline cellulose; isopropyl alcohol; povidone; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olamlo hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.
apo-olmesartan/amlodipine/hctz 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.
olamlo hct 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack
accord healthcare pty ltd - amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olamlo hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.
apo-olmesartan/amlodipine/hctz 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; magnesium stearate; lactose monohydrate; povidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - apo-olmesartan/amlodipine/hctz 20/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.
apo-olmesartan/amlodipine/hctz 40/10/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg film-coated tablet blister pack
arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; silicified microcrystalline cellulose; povidone; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.
milbactor 16 mg/40 mg film-coated tablets for cats weighing at least 2 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 16, 40 mg/tablet - milbemycin oxime, combinations - cats - ectoparasiticide
milbactor 4 mg/10 mg film-coated tablets for small cats and kittens weighing at least 0.5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 4, 10 mg/tablet - milbemycin oxime, combinations - cats - endoparasiticide
milprazon 16 mg/40 mg film-coated tablets for cats weighing at least 2 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 16, 40 mg/tablet - milbemycin oxime, combinations - cats - endoparasiticide
milprazon 4 mg/10 mg film-coated tablets for small cats and kittens weighing at least 0.5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 4, 10 mg/tablet - milbemycin oxime, combinations - cats - endoparasiticide
voriconazole sandoz voriconazole 50mg film-coated tablet blister pack
sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.